• About us
• Contact

Advertisement

Collaboration › Details

Argenx–JPMorgan Chase: investor conference, 202101 supply service Argenx presents at JP Morgan Healthcare Conference 2021

 

	Period	2021-01-11
	Partner, 1st	Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX)
	Today	Argenx SE (Euronext + Nasdaq: ARGX)
	Group	Argenx (Argen-X) (Group)
	Partner, 2nd	J.P. Morgan Securities LLC
	Group	JPMorgan Chase (Group)
	Product	J.P. Morgan 39th Annual Healthcare Conference 2021 DIGITAL
	Product 2	therapeutic antibody
	Person	Van Hauwermeiren, Tim (Argen-X 201101 CEO before Ablynx BusDev Manager before P&G)
	Person 2	DelGiacco, Beth (Argenx 201806– VP Investor Relations before Stern IR)

Argenx SE. (1/4/21). "Press Release: Argenx to Present at 39th Annual J.P. Morgan Healthcare Conference". Breda & Ghent.

argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 8:20 a.m. ET.

A live webcast of the presentation will be available on the Company’s website at www.argenx.com. A replay of the webcast will be available for 90 days following the presentation.


About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, and Japan. For more information, visit www.argenx.com and follow us on LinkedIn.


For further information, please contact:

Beth DelGiacco, Vice President, Corporate Communications & Investor Relations
+1 518 424 4980
bdelgiacco@argenx.com

Joke Comijn, Director Corporate Communications & Investor Relations (EU)
+32 (0)477 77 29 44
+32 (0)9 310 34 19
jcomijn@argenx.com

Record changed: 2022-01-02

Advertisement

More documents for Argenx (Argen-X) (Group)

• [1] Argenx SE. (7/18/23). "Press Release: Argenx Raises $1.1 Billion in Gross Proceeds in a Global Offering". Amsterdam....
• [2] Argenx SE. (7/17/23). "Press Release: Argenx Reports Positive Topline Data from ADHERE Study of Vyvgart Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy". Amsterdam....
• [3] Argenx SE. (7/17/23). "Press Release: Argenx Announces Launch of Proposed Global Offering". Amsterdam....
• [4] Argenx SE. (4/17/23). "Press Release: Argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology". Amsterdam....
• [5] Argenx SE. (3/29/22). "Press Release: Argenx Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs". Breda....
• [6] Argenx SE. (3/23/22). "Press Release: Argenx Raises $700 Million in Gross Proceeds in a Global Offering". Breda....
• [7] TVM Capital Life Science. (1/18/22). "Press Release: TVM Capital Life Science Promotes Dr. Sascha Berger and Dr. Alain Thibault to General Partner". Munich & Montréal....
• [8] Argenx SE. (12/20/21). "Press Release: Argenx Announces U.S. Food and Drug Administration (FDA) Approval of Vyvgart (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis". Darmstadt....
• [9] Argenx SE. (9/3/21). "Press Release: Argenx to Present at Upcoming Investor Conferences". Breda....
• [10] Argenx SE. (7/14/21). "Press Release: Argenx to Host Virtual R&D Day on July 20, 2021". Breda....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.